|1.||Petro, Thomas M: 2 articles (09/2007 - 09/2006)|
|2.||Akira, Shizuo: 2 articles (11/2003 - 01/2003)|
|3.||Hemmi, Hiroaki: 2 articles (11/2003 - 01/2003)|
|4.||Swaggerty, C L: 1 article (04/2012)|
|5.||He, H: 1 article (04/2012)|
|6.||Duke, S E: 1 article (04/2012)|
|7.||Kogut, M H: 1 article (04/2012)|
|8.||Genovese, K J: 1 article (04/2012)|
|9.||Bagnaud-Baule, Audrey: 1 article (01/2012)|
|10.||Lowther, Sue: 1 article (01/2012)|
12/01/2000 - "We conducted a double-blind randomized phase I study to evaluate the safety, pharmacokinetics, and immunologic effects of single ascending doses of loxoribine in patients with advanced cancer. "
11/01/2003 - "Loxoribine (7-allyl-7,8-dihydro-8-oxo-guanosine) acts as synthetic adjuvant in anti-tumor responses. "
12/01/2000 - "Loxoribine is safe at doses up to 10 mg/kg in patients with advanced cancer, and produces modest immunologic effects. "
12/01/2000 - "Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer."
09/15/2007 - "Excitingly, IFN-gamma secretion was significantly increased when NK cells were stimulated with poly(I:C) or loxoribine and IL-12, and NKG2D engagement was induced by coculture with MICA+ tumor cells in a PI3K-dependent manner. "
04/01/2012 - "The results obtained in this study indicate that there is a potential application for using loxoribine to increase protection of young chicks when they are most susceptible to infections with Salmonella."
09/30/2006 - "In contrast to overexpressed IRF-1, IRF-5, and IRF-7, which stimulated p35 promoter reporter activity, overexpressed IRF-3 repressed p35 promoter activity in response to TMEV infection, loxoribine, IFN-gamma/LPS, but not IFN-gamma alone. "
09/01/2007 - "TMEV infection or stimulation with poly (I:C), a TLR3 agonist, or loxoribine, a TLR7 agonist, induced expression of IL-23 and IFN-beta in RAW264.7 cells. "
09/30/2006 - "Macrophages from ADD-susceptible SJL/J mice responding to Theiler's Virus (TMEV) infection, the TLR7 agonist loxoribine, or the TLR4 agonist-LPS expressed less IL-12 p35 but more IL-12/23 p40 and IFN-beta than macrophages from ADD-resistant B10.S mice. "
01/22/2003 - "TLR7 recognizes small synthetic immune modifiers including imiquimod, R-848, loxoribine, and bropirimine, all of which are already applied or promising for clinical use against viral infections and cancers. "
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
06/01/1996 - "Investigation of the biological actions of loxoribine in chronic lymphocytic leukemia (CLL) was undertaken because of the pervasive immunostimulatory effects of the nucleoside on normal B cells. "
11/15/1994 - "Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle."
07/01/1997 - "Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells."
11/15/1994 - "Leukemic B cells from a majority of patients with chronic lymphocytic leukemia (CLL) enter the cell cycle upon stimulation in vitro with loxoribine, a potent 7,8-disubstituted guanine ribonucleoside immunostimulant. "
03/01/1999 - "Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells."
|4.||Chronic Hepatitis B
|5.||Human Influenza (Influenza)
|2.||Interleukin-12 (IL 12)
|5.||Interleukin-23 (Interleukin 23)
|6.||Toll-Like Receptors (Toll-Like Receptor)
|9.||Hepatitis B e Antigens